Business Wire

Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook

Share

Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook. With over 26 years’ experience partnering with start-up to mid-size biotech and pharmaceutical companies, Veristat excels in supporting complex trials across a wide range of therapeutic areas. Always taking a patient-centric approach, the company is highly innovative and formulates flexible solutions that benefit patients and attract them to participate in clinical trials.

In today’s digital world, patients proactively participate in their health plans and seek information on various diseases and treatments online,” stated Shaheen Limbada, Executive Vice President, Global Clinical Operations at Veristat, “Realizing this, we’ve focused on targeting the potential and intended participants for trials through digital media and online platforms. Veristat curates highly relevant and appropriate patient populations by leveraging in-house, customized marketing, and search engine optimization strategies. These strategies improve patient recruitment and retention success rates for trials efficiently and cost-effectively.”

Responding rapidly to the COVID-19 situation and taking a thoughtful scientific approach towards it, Veristat has expanded virtual ecosystems for clients specific to their needs ensuring continuity of ongoing and new clinical trials. The company has developed a “rescue study methodology,” comprised of a series of non-conventional good clinical practice (GCP) compliant tactics for supporting trials. By setting up virtual sites, Veristat ensures the continuity of studies by allowing patients to participate in trials remotely through telemedicine patient portals and at-home visits. Access to the required equipment and medical supplies promptly enabled patients to continue the programs and clients to begin new programs. The company safeguarded patient recruitment throughout the pandemic with its rescue strategies. This included web console technology for staff to interact, patient portals for patients and physicians to communicate via telemedicine, and secure document exchange portals for the collection of study documentation.

Applying knowledge from the various COVID-19 trials that they have conducted, Veristat established a COVID taskforce to centralize the lessons learned and to leverage the most successful approaches on the different trials to focus the trial activities to achieve the highest enrollment. “We are continuously working on advancing the trials in a productive and impactful way unique for each clinical setting to ensure we respond to a highly elevated sense of urgency due to the pandemic and evolving client needs,” stated Patrick Flanagan, Chief Executive Officer at Veristat.

Click here for access to the full interview on Pharma Tech Outlook.

About Veristat:

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, cell and gene therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HP Becomes Sisvel Wi-Fi 6 Pool Licensee, Ending Disputes with Wilus, Huawei and Philips18.11.2025 11:58:00 EET | Press release

HP Inc and Sisvel have concluded an agreement for the Palo Alto-based global technology leader to become a licensee of the Sisvel Wi-Fi 6 patent pool. The deal follows a mediation process ordered by Judge Rodney Gilstrap, of the US District Court for the Eastern District of Texas, as part of patent infringement litigation brought against HP by Wilus Institute of Standards and Technology, a licensor in the pool. The agreement not only ends the Wilus suit, but also actions launched against HP by other Sisvel Wi-Fi 6 pool licensors, Huawei and Philips. HP now has one-stop access to approximately 2,000 patents (245 patent families) recognised to date, through the pool’s process of independent patent evaluations, as essential to the 802.11ax Wi-Fi 6 standard. Close to 40 entities license the patents in the Sisvel Wi-Fi 6 patent pool. In addition to HP Inc, these include other recent additions such as Cisco, Netgear and Acer. “We are grateful to HP for the constructive way in which they enga

Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises18.11.2025 11:00:00 EET | Press release

GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces. Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in black-box autonomous systems – by building trustworthy, transparent, and governed AI agents that accelerate the customer experience (CX) market

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 10:05:00 EET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 10:00:00 EET | Press release

SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth. “We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Jo

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release

Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye